The U.S. Food and Drug Administration has recalled the sale and consumption of prescription and over-the-counter ranitidine (commonly referred to as Zantac). This recall came after an ongoing investigation found unacceptable levels of N-Nitrosodimethylamine (NDMA) in ranitidine medications. The NDMA impurity is commonly found in low levels in Zantac, but researchers have found that these levels increase over time when stored at higher than room temperatures, resulting in unacceptable and potentially harmful levels of the impurity.
While low levels of NDMA are commonly ingested in foods and in water, the higher levels of NDMA that are being found in Zantac increase the risk of cancer in humans. Even under normal storage conditions, NDMA levels in Zantac can still increase significantly when being transported, distributed, and handled by consumers. It should also be noted that the older the Zantac product is, the greater the level of NDMA.
The FDA is advising that all manufacturers of Zantac remove their products from the market immediately. Additionally, consumers taking over-the-counter Zantac should stop consumption, dispose of the product correctly, and not buy more. Those taking prescription Zantac should speak to their health care provider about other treatment options, as there are multiple drugs approved for the same or similar uses as Zantac that do not carry the same risks from NDMA.
Recoverable damages in pharmaceutical injury cases include your medical bills, lost wages, future earnings, loss of enjoyment of life, inconvenience, and pain and suffering. If you have been a victim of this recall on Zantac, and you live in the state of Florida, contact the personal injury attorneys at Beltz & Beltz today.
